Asset for Fibrotic Disease

The Challenge:

TherapeutAix was approached by a US-based biotech company to review an asset that they were considering repositioning for fibrotic disease. The company asked for specific help in reviewing existing data, defining the steps then required to take the asset to IND-enabling studies and into the clinic. 

The Action:

The task was to review the existing data and background information and to provide an opinion on how the asset could be positioned for the treatment of fibrotic disease. 

The TherapeutAix team reviewed the background literature and existing data with respect to fibrosis. Gaps in the pre-clinical data package were identified that would need to be filled to progress the asset for fibrosis. Suitable and decision-making PK/PD experiments, in vitro and ex vivo, biomarker-led studies were proposed and subsequently prosecuted by us, using our network of CROs. Additionally, potential clinical positioning options were reviewed, and proposals prepared and presented to the company’s Board for consideration.  

The Result:

A comprehensive review of the asset, landscape, potential positioning was prepared and provided to the Company, together with decision-making data from pre-clinical studies. 

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.